Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "Non-small cell lung cancer" wg kryterium: Wszystkie pola

  Lista filtrów
Wyrównaj
Wyświetlanie 1-15 z 16
Tytuł:
Efficacy of crizotinib therapy for a patient with non-small cell lung cancer with ALK gene rearrangement – case report and review of current therapeutic options
Autorzy:
Bargiel, J.B.
Cabaj, J.
Chmielewska, I.
Milanowski, J.
Powiązania:
https://bibliotekanauki.pl/articles/2098542.pdf
Data publikacji:
2021
Wydawca:
Instytut Medycyny Wsi
Tematy:
non-small cell lung cancer
crizotinib
therapy
gene rearrangement
tyrosine kinase inhibitor
patient
Opis:
Introduction. Currently, nearly 23,000 cases of lung cancer are diagnosed in Poland annually, of which 5% are cases with rearrangements in the ALK gene. In recent years, tremendous progress has been made in understanding the genetic makeup of this type of cancer, which has enabled the use of new therapies, in particular, molecularly targeted drugs. Crizotinib is the first oral small molecule inhibitor of ALK, MET and ROS1 receptor tyrosine Kinases approved by the European Medicines Agency(EMA). Case report. The paper presents the case of a 62-year-old patient diagnosed with non-small cell lung cancer with rearrangement in the ALK gene in stage IV of the disease. The patient was qualified for treatment with crizotinib under the B6 drug programme. Treatment started in May 2019. During treatment, assessment was made at 3 control points, where the first and second showed a partial response according to the RECIST 1.1 scale; in the next assessment, the response was maintained in the form of disease stabilization.
Źródło:
Journal of Pre-Clinical and Clinical Research; 2021, 15, 3; 151-154
1898-2395
Pojawia się w:
Journal of Pre-Clinical and Clinical Research
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Differentiation by random amplified polymorphic DNA-polymerase chain reaction (RAPD-PCR) of Candida albicans isolated from upper respiratory tract in patients with non-small cell lung cancer
Autorzy:
Biernasiuk, Anna
Korona-Głowniak, Izabela
Grzegorczyk, Agnieszka
Malm, Anna
Powiązania:
https://bibliotekanauki.pl/articles/1039202.pdf
Data publikacji:
2014
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
RAPD-PCR
Candida albicans
upper respiratory tract
genetic diversity
Opis:
Cancer patients are predisposed to fungal infections caused by Candida albicans, especially to oral or respiratory tract candidiasis. The aim of this study was to estimate genetic diversity by RAPD-PCR (random amplified polymorphic DNA-polymerase chain reaction) of C. albicans isolated from upper respiratory tract of 100 patients with non-small cell lung cancer. Among 52 strains, 34 genotypes were defined. 10 clusters comprising 28 (53.85%) isolates with similarity coefficient ≥ 80% were formed. The remaining 24 (46.15%) isolates represented individual genotypes. The RAPD-PCR technique revealed genomic variability within C. albicans isolated from upper respiratory tract of the cancer patients.
Źródło:
Acta Biochimica Polonica; 2014, 61, 4; 727-729
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
First report of the oncolytic effect of EHV-1 on the non-small lung cancer – in vitro studies
Autorzy:
Chodkowski, M.
Słońska, A.
Bartak, M.
Bańbura, M.W.
Cymerys, J.
Powiązania:
https://bibliotekanauki.pl/articles/2087133.pdf
Data publikacji:
2021
Wydawca:
Polska Akademia Nauk. Czytelnia Czasopism PAN
Tematy:
EHV-1
adenocarcinoma cell line
oncolytic virus
Źródło:
Polish Journal of Veterinary Sciences; 2021, 24, 4; 607-610
1505-1773
Pojawia się w:
Polish Journal of Veterinary Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Wstępne wyniki zastosowania techniki interferencji RNA do wyciszania ekspresji genów MMP-2 i MMP-9 kodujących metaloproteinazy macierzy pozakomórkowej w komórkach raka płuca linii A549
Preliminary results of application of RNA interference technique to downregulate expression of matrix metalloproteinases: MMP-2 and MMP-9 genes in A549 lung cancercells
Autorzy:
Galilejczyk, Anna
Sypniewski, Daniel
Bednarek, Ilona
Powiązania:
https://bibliotekanauki.pl/articles/1034847.pdf
Data publikacji:
2013
Wydawca:
Śląski Uniwersytet Medyczny w Katowicach
Tematy:
mmp-2
mmp-9
interferencja rna
niedrobnokomórkowy rak płuca
rna interference
non-small cell lung cancer
Opis:
INTRODUCTION Tumor growth, invasion of surrounding tissues and metastasis require degradation of the protein components of the extracellular matrix and basement membranes. Matrix metalloproteinases play a major role in the process of digesting ECM components and intensify the adverse effects around the growing tumor. Increased expression and activity of MMP-2 and MMP-9 have been observed in many malignancies. The aim of this study was to design and apply a method based on RNA interference to reduce the expression of gelatinases. MATERIAL AND METHOD Silencing oligonucleotides directed at MMP-2 and MMP-9 genes were designed based on the mRNA sequences (GenBank) in the sirna program. Gene constructs were synthesized and cloned into the pSUPER.neo vector. After verifying their correctness, plasmid DNA was used to transfect human non-small cell lung cancer A549 cells. The changes in the level of MMP-2 and MMP-9 mRNA were determined by the Real TimeTM PCR technique. RESULTS After 24 hours of shRNA/MMP-2 construct application, no changes in the MMP-2 mRNA level were observed. In turn, after 10 days a 33.1% reduction was noticed. Downregulation of the MMP-9 gene was more efficient. After 24 hours of using plasmids carrying shRNA/MMP-9 constructs, a 95.6% decrease in the number of MMP-9 mRNA copies was observed. After 10 days, the level of MMP-9 gene expression was 26.2% in comparison to the mRNA level established for the control cells. CONCLUSIONS The RNA interference technique can be successfully used to downregulate the expression of MMP-2 and MMP-9 genes. The obtained results confirmed that our shRNA/MMP-2 and shRNA/MMP-9 constructs are capable of reducing the mRNA level in the non–small cell lung cancer A549 cell line.
W S T Ę P Wzrost guzów nowotworowych, inwazja otaczających tkanek oraz powstawanie przerzutów wymagają degradacji białkowych składników macierzy pozakomórkowej oraz błon podstawnych. Metaloproteinazy macierzy pozakomórkowej odgrywają podstawową rolę w trawieniu składników macierzy i nasilają wiele niekorzystnych zmian w otoczeniu rozwijającego się nowotworu. W przebiegu licznych nowotworów szczególnie podkreśla się negatywną rolę metaloproteinaz należących do grupy żelatynaz. Celem pracy było zaprojektowanie i zastosowanie metody wykorzystującej zjawisko interferencji RNA, pozwalającej obniżyć ekspresję genów MMP-2 i MMP-9. MATERIAŁ I METODY Materiał do badań stanowiły ludzkie komórki nowotworowe niedrobnokomórkowego raka płuca linii A549. Wyciszające konstrukcje genetyczne zaprojektowano opierając się na sekwencjach mRNA dla MMP-2 i MMP-9, pochodzących z bazy danych GenBank, za pomocą programu komputerowego sirna, a następnie wklonowano do plazmidu pSUPER.neo. Po zweryfikowaniu prawidłowości otrzymanych konstrukcji, plazmidowy DNA wykorzystano do transfekcji komórek eukariotycznych A549. Do oceny zmian poziomu ekspresji mRNA MMP-2 i MMP-9 zastosowano metodę Real Time TM RT – PCR. WYNIKI W komórkach A549, do których wprowadzono zaprojektowane konstrukcje shRNA/MMP-2, po 24 godzinach nie zaobserwowano zmian poziomu mRNA MMP-2, natomiast po 10 dniach odnotowano 33,1% spadek ekspresji tego genu. Wydajniejszy był proces wyciszania ekspresji genu MMP-9 , gdyż w komórkach transfekowanych plazmidami niosącymi konstrukcje shRNA/MMP-9 zaobserwowano 95,6% spadek liczby kopii mRNA MMP- 9 już po 24 godzinach. Po 10 dniach poziom ekspresji genu MMP-9 wynosił 26,2% w stosunku do poziomu ustalonego dla komórek kontrolnych. WNIOSKI Technika interferencji RNA może być wykorzystywana do wyciszania ekspresji genów żelatynaz związanych z procesem metastazy nowotworów. Wstępne wyniki potwierdziły zdolność zaprojektowanych konstrukcj i genetycznych do potranskrypcyjnego wyciszania ekspresji tychże genów w komórkach niedrobnokomórkowego raka płuca linii A549
Źródło:
Annales Academiae Medicae Silesiensis; 2013, 67, 3; 157-165
1734-025X
Pojawia się w:
Annales Academiae Medicae Silesiensis
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Reference genes for gene expression studies on non-small cell lung cancer
Autorzy:
Gresner, Peter
Gromadzinska, Jolanta
Wasowicz, Wojciech
Powiązania:
https://bibliotekanauki.pl/articles/1040589.pdf
Data publikacji:
2009
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
non-small cell lung cancer
reference genes
data normalization
real-time PCR
gene expression
Opis:
Study Objective: The aim of this study was to test a panel of 6 reference genes in order to identify and validate the most suitable reference genes for expression studies in paired healthy and non-small cell lung cancer tissues. Method: Quantitative real-time PCR followed by the NormFinder- and geNorm-based analysis was employed. The study involved 21 non-small cell lung cancer patients. Results: The analysis of experimental data revealed HPRT1 as the most stable gene followed by RPLP0 and ESD. In contrast, GAPDH was found to be the least stable gene. HPRT1 together with ESD was revealed as the pair of genes introducing the least systematic error into data normalization. Validation by bootstrap random sampling technique and by normalizing exemplary gene expression data confirmed the results. Conclusion: Although HPRT1 and ESD may by recommended for data normalization in gene expression studies on non-small cell lung cancer, the suitability of selected reference genes must be unconditionally validated prior to each study.
Źródło:
Acta Biochimica Polonica; 2009, 56, 2; 307-316
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
Autorzy:
Kardas, Joanna
Buraczewska, Agnieszka
Chrom, Paweł
Waśko-Grabowska, Anna
Młot, Beata
Szczylik, Cezary
Powiązania:
https://bibliotekanauki.pl/articles/773534.pdf
Data publikacji:
2017
Wydawca:
Medical Education
Tematy:
endothelial growth factor receptor
non-small cell lung cancer
tyrosine kinase inhibitor
Opis:
Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objective: The evaluation of the efficacy and toxicity of TKI drugs in NSCLC patients treated in single centre. Material and methods: NSCLC patients treated with TKI (gefitinib, erlotynib, afatinib) between 2012– 2016 were retrospectively analysed. We evaluated: overall response rate (ORR) which is the sum of complete responses (CR) and partial remissions (PR), progression free survival (PFS), overall survival (OS) and adverse events (AE) according to CTCAE (Common Terminology Criteria for Adverse Events) scale. Results: The study group were 16 patients ORR was 50% (CR: 1, PR: 7). Median PFS and OS was 8,7 and 22,9 months respectively. Adverse events observed mainly in stage 1 and 2 were related to hyponatraemia, hyperbilirubinemia, skin toxicity and mucositis. There was one death reported due to infectious complications. Conclusion: The efficacy and toxicity of TKI in study group were found to be similar to those described in the literature.
Źródło:
OncoReview; 2017, 7, 2; 92-97
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Leczenie niedrobnokomórkowego raka płuca (NDRP) w stadium zaawansowania miejscowego lub rozsiewu w kontekście programu lekowego
Advanced or metastatic non-small-cell lung cancer treatment – new Polish government regulation
Autorzy:
Kowalski, Dariusz M.
Krawczyk, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/1066056.pdf
Data publikacji:
2013
Wydawca:
Medical Education
Tematy:
NDRP
docetaksel
erlotynib
gefitynib
pemetreksed
program lekowy
Opis:
The article presents the non-small-cell lung cancer current treatment recommendations in consideration of Polish government regulation.
W artykule przedstawiono aktualne zalecenia leczenia niedrobnokomórkowego raka płuca wobec ustaleń aktualnie obowiązującego programu lekowego.
Źródło:
OncoReview; 2013, 3, 2; 96-101
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Association between polymorphisms in CHRNA3 and PHACTR2 gene and environment and NSCLC risk in Chinese population
Autorzy:
Lou, Guangyuan
Zhang, Yongjun
Bao, Wenlong
Deng, Dehou
Powiązania:
https://bibliotekanauki.pl/articles/1039210.pdf
Data publikacji:
2014
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
Non-small cell lung cancer
phosphatase and actin regulator 2 (PHACTR2)
cholinergic receptor
nicotinic
alpha 3 (CHRNA3)
single-nucleotide polymorphism
Opis:
Aims. This study aimed to investigate CHRNA3 (rs8040868) and PHACTR2 (rs9390123) single-nucleotide polymorphisms (SNPs) for association with non-small-cell lung cancer (NSCLC) risk in a Chinese population, and whether the environment affects the genetic polymorphisms. Methods. This case and control study included 500 NSCLC patients and 500 age-matched healthy controls. CHRNA3 (rs8040868) and PHACTR2 (rs9390123) SNPs were genotyped and associated for NSCLC risk by computing the odds ratio and 95% confidence interval from multivariate unconditional logistic regression analyses with adjustment of age. Results. The minor allele frequency (MAF) of CHRNA3 (rs8040868) and PHACTR2 (rs9390123) was 0.350 (C) and 0.397 (C), respectively. The frequencies of genotype and allele in CHRNA3 (rs8040868) and PHACTR2 (rs9390123) were not significantly different between the cases and controls, or between either of the subgroups. Conclusion. Although rs8040868 and rs9390123 SNPs are not associated with NSCLC risk in Chinese population, the results strongly suggest that geographical agents interact with human genetic polymorphism independent of ethnic background.
Źródło:
Acta Biochimica Polonica; 2014, 61, 4; 765-768
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Life Expectancy in Patients With Stage III A Non-small Cell Lung Cancer (NSCLC) Treated With Neoadjuvant Chemoradiotherapy (NCRT), Neoadjuvant Chemotherapy (NCT), Neoadjuvant Chemotherapy + Adjuvant Radiation Therapy (NCT + Adjuvant RT)
Przewidywana długość życia u pacjentów z niedrobnokomórkowym rakiem płuca w stadium III A (NSCLC) poddanych neoadjuwantowej chemioradioterapii (NCRT), neoadjuwantowej chemioterapii (NCT), neoadjuwantowej chemioterapii + adjuwantowej radioterapii (NCT + adjuwantowa RT)
Autorzy:
Maliarchuk, Katerina
Ganul, Andrey
Borisyuk, Bogdan
Bororov, Leonid
Shevchenko, Anatoly
Sovenko, Vladimir
Kutsenko, Lubov
Powiązania:
https://bibliotekanauki.pl/articles/2159225.pdf
Data publikacji:
2022-12-30
Wydawca:
Akademia Bialska Nauk Stosowanych im. Jana Pawła II w Białej Podlaskiej
Tematy:
neoadjuvant therapy
pneumonectomy
lobectomy
non-small cell lung cancer
overall survival
terapia neoadjuwantowa
pneumonektomia
lobektomia
niedrobnokomórkowy rak płuca
choroby
przeżycie całkowite
Opis:
Background. This work is а comparative study of survival in patients with stage III A non-small cell lung cancer (NSCLC) treated with neoadjuvant chemoradiotherapy (NCRT), neoadjuvant chemotherapy (NCT) and neoadjuvant chemotherapy and adjuvant radiation therapy (NCT + adjuvant RT). Material and methods. Three groups of 65 people were selected. The first group received NCT, the second group – NCT, and the third group – NCT + adjuvant radiation therapy. The NCRT group received radiation therapy of 30 Gy. Survival was assessed using the Kaplan and Mayer scale and according to the log rank criteria. Results. The statistical criterion for NCRT in relation to NCT was -3.51279, r=0.00044. The statistical criterion for NCRT in relation to NCT + adjuvant RT was -2.88568, r=0.00391. Less reliable dependence was observed between NCT and NCT + adjuvant RT (the statistical criterion =1.809508, p=0.070307). Conclusions. Performing NCT, NCRT or NCT + RT and the status of complete morphological response (CMR) during the revision of histological material, it is possible to predict survival for a period of up to 36 months. NCRT is the optimal method of treatment.
Wprowadzenie. Niniejsza praca stanowi badanie porównawcze przeżycia u pacjentów z niedrobnokomórkowym rakiem płuca w stadium III A (NSCLC) w leczeniu neoadjuwantową chemioradioterapią (NCRT), neoadjuwantową chemioterapią (NCT) oraz neoadjuwantową chemioterapią i adjuwantową radioterapią (NCT + adjuwantowa RT). Materiał i metody. Wyłoniono 3 grupy po 65 osób. Pierwsza grupa otrzymała NCT, druga grupa – NCRT, a trzecia grupa – NCT + radioterapię adjuwantową. Grupa NCRT otrzymała radioterapię w dawce 30 Gy. Przeżycie oceniano za pomocą skali Kaplana i Mayera oraz według kryteriów log rank. Wyniki. Kryterium statystyczne NCRT w stosunku do NCT wyniosło -3,51279, r=0,00044. Kryterium statystyczne NCRT w stosunku do NCT + adjuwantowej RT wyniosło -2,88568, r=0,00391. Mniej wiarygodna zależność została zaobserwowana między NCT a NCT + adjuwantowa RT (kryterium statystyczne = 1,809508, p=0,070307). Wnioski. Wykonując NCT, NCRT lub NCT + RT oraz status całkowitej odpowiedzi morfologicznej (CMR) podczas rewizji materiału histolog
Źródło:
Health Problems of Civilization; 2022, 16, 4; 302-311
2353-6942
2354-0265
Pojawia się w:
Health Problems of Civilization
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Differential Notch1 and Notch2 expression in non-small cell lung cancer
Autorzy:
Pancewicz, J.
Bernatowicz, P.L.
Powiązania:
https://bibliotekanauki.pl/articles/1918837.pdf
Data publikacji:
2019
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
NOTCH1
NOTCH2
NSCLC
HBEpC
Opis:
Introduction: NOTCH signaling can be deregulated in non-small cell lung cancer and can have oncogenic or tumor suppressive functions. NOTCH1 is regulated equally with NOTCH2, and the stability of the expression of those Notch receptors could determine the biological functions of lung cancer cells. Purpose: To estimate expression level of NOTCH2 receptor in diverse NSCLC cell lines. Furthermore, we compared the mRNA level of NOTCH2 expression to the level of NOTCH1 expression. Materials and methods: We have evaluated the mRNA manifestation of NOTCH1 and NOTCH2 genes by using quantitative real time method (RT-PCR). Moreover, we associated the results from NSCLC cells with results achieved in non-cancerous human bronchial epithelial cells (HBEpC). Results: The expression level of NOTCH1 and NOTCH2 was downregulated in NSCLC cell lines, when related to HBEpC. Nevertheless, the decrease in NOTCH1 expression was significant, whereas NOTCH2 was not much different from the expression in control cells. Conclusions: We conclude that NOTCH1 and NOTCH2 most likely have different biological function in NSCLC. They are active in NSCLC cell lines; nonetheless both are downregulated in lung cancer cells used in this study. Moreover, NOTCH2 expression is comparatively higher than NOTCH1 expression.
Źródło:
Progress in Health Sciences; 2019, 1; 8-12
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Human bronchial epithelial cells as a good control for evaluation potential therapeutic Notch signaling in non-small cell lung cancer
Autorzy:
Pancewicz, J.
Bernatowicz, P.L.
Golec, P.
Powiązania:
https://bibliotekanauki.pl/articles/1918632.pdf
Data publikacji:
2018-06-18
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Notch
NSCLC
HBEpC
Opis:
Purpose: Notch signaling is often deregulated in non-small cell lung cancer (NSCLC), but little is known about the initial endogenous mRNA status of Notch ligands and receptors. Therefore, the aim of this study was to evaluate expression level of NOTCH1 receptor and Notch ligands, such as delta like ligands (DLL1, DLL3, DLL4), and jagged ligands (JAG1, JAG2), as well as target gene-hes family bHLH transcription factor 1 (HES1) in diverse NSCLC cell lines. Materials and Methods: We have investigated the mRNA expression of chosen genes by using quantitative real time method (RT-PCR). We compared the results from NSCLC cells with results obtained in non-cancerous human bronchial epithelial cells (HBEpC). We also measured NOTCH1 expression in A549 cells, before and after treatment with γ-secretase inhibitor (GSI). Results: The expression level of NOTCH1, HES1, JAG1 and JAG2 was downregulated when compared to HBEpC. The expression of Notch ligand DLL1 was lower in all cancer cell lines, but mRNA level of DLL3 was elevated in H1299 and A549 cells when related to HBEpC. The mRNA level of DLL4 was higher in H520 and in A549 cell lines. Moreover, the mRNA level of NOTCH1 dropped down after GSI treatment, in addition A549 cells proliferated slower after drug implementation. Conclusions: We conclude that non-cancerous HBEpC cells could serve as a good control for Notch mRNAs expression analysis in NSCLC. Moreover, GSI-treated cells could inhibit proliferation through suppressing NOTCH1 in A549 cells. Keywords: Notch, NSCLC, HBEpC
Źródło:
Progress in Health Sciences; 2018, 8(1); 7-13
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Long non-coding RNA and Notch regulation in non-small cell lung cancer
Autorzy:
Pancewicz, Joanna
Powiązania:
https://bibliotekanauki.pl/articles/1918915.pdf
Data publikacji:
2020-06-10
Wydawca:
Uniwersytet Medyczny w Białymstoku
Tematy:
Notch
non-small cell lung cancer
lncRNAs
Opis:
Non-small cell lung cancer is one of the most commonly diagnosed cancer with a very high mortality rate. Trying to understand the mechanisms underlying the progression of this type of cancer, it is necessary to evaluate the changes occurring at molecular level in cancer cells. Besides the widely studied signaling pathways and genes which are dysregulated in NSCLC, there is a large group of non-coding RNAs involved in cancer pathogenesis. Those RNAs are tissue specific heterogeneous class of RNAs that play many functions in physiological condition in cells, nevertheless current data has shown that lncRNAs are also functional in different types of cancer. Moreover, it has been suggest that lncRNAs are involved in cancer progression by controlling key signaling pathways involved in diverse types of tumors. Notch signaling is one of those pathways, very often deregulated in NSCLC. Therefore in this review I summarized recent outcomes according the importance of lncRNAs in regulation of Notch pathway in the pathogenesis of NSCLC.
Źródło:
Progress in Health Sciences; 2020, 10(1); 108-122
2083-1617
Pojawia się w:
Progress in Health Sciences
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
Identification of serum proteome components associated with progression of non-small cell lung cancer
Autorzy:
Pietrowska, Monika
Jelonek, Karol
Michalak, Malwina
Roś, Małgorzata
Rodziewicz, Paweł
Chmielewska, Klaudia
Polański, Krzysztof
Polańska, Joanna
Gdowicz-Kłosok, Agnieszka
Giglok, Monika
Suwiński, Rafał
Tarnawski, Rafał
Dziadziuszko, Rafał
Rzyman, Witold
Widłak, Piotr
Powiązania:
https://bibliotekanauki.pl/articles/1039297.pdf
Data publikacji:
2014
Wydawca:
Polskie Towarzystwo Biochemiczne
Tematy:
cancer staging
early detection
lung cancer
proteomics
serum biomarkers
Opis:
The aim of the present study was to perform comparative analysis of serum from patients with different stages of non-small cell lung cancer (NSCLC) using the three complementary proteomic approaches to identify proteome components associated with the progression of cancer. Serum samples were collected before any treatment from 200 patients with NSCLC, including 103 early stage, 64 locally advanced and 33 metastatic cancer samples, and from 200 donors without malignancy. The low-molecular-weight fraction of serum proteome was MALDI-profiled in all samples. Serum proteins were characterized using 2D-PAGE and LC-MS/MS approaches in a representative group of 30 donors. Several significant differences were detected between serum samples collected from patients with early stage cancer and patients with locally advanced cancer, as well as between patients with metastatic cancer and patients with local disease. Of note, serum components discriminating samples from early stage cancer and healthy persons were also detected. In general, about 70 differentiating serum proteins were identified, including inflammatory and acute phase proteins already reported to be associated with the progression of lung cancer (serum amyloid A or haptoglobin). Several differentiating proteins, including apolipoprotein H or apolipoprotein A1, were not previously associated with NSCLC. No significant differences in patterns of serum proteome components were detected between patients with adenocarcinoma and squamous cell carcinoma. In conclusion, we identified the biomarker candidates with potential importance for molecular proteomic staging of NSCLC. Additionally, several serum proteome components revealed their potential applicability in early detection of the lung cancer.
Źródło:
Acta Biochimica Polonica; 2014, 61, 2; 325-331
0001-527X
Pojawia się w:
Acta Biochimica Polonica
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
The current state of knowledge on small cell and non-small cell lung cancer and the position of durvalumab immunotherapy in lung cancer treatment
Autorzy:
Poboży, Kamil
Domańska, Julia
Domański, Paweł
Powiązania:
https://bibliotekanauki.pl/articles/3200762.pdf
Data publikacji:
2023-01-24
Wydawca:
Medical Education
Tematy:
PD-L1
immunotherapy
durvalumab
neoplasm
oncology
SCLC
NSCLC
Opis:
Lung cancer is the second most frequently diagnosed cancer and the leading cause of cancer-related deaths in the world. These statistics make lung cancer one of the most important targets for modern medicine. The identification of multiple risk factors, including tobacco smoking, has been fundamental in understanding the disease. Late-stage detection is a significant contributor to the high mortality rate of lung cancer. Nonetheless, the role of screening is still debatable. The selection of therapy is primarily based on distinguishing between small-cell and non-small cell lung cancer. Despite the major differences in treatment, in both types in specific situations the treatment involves durvalumab – a monoclonal antibody targeting the programmed cell death ligand 1 molecule, which is often present on tumor cells and protects them against the patient’s immune system. The efficacy of durvalumab has been demonstrated in two randomized, multicenter clinical trials. The aim of this study is to summarize the current state of knowledge about lung cancer and durvalumab. Despite the current 5-year survival rate of 19% in lung cancer, the development of immunotherapeutics such as durvalumab may be the key to improving the unfavorable prognosis of lung cancer in the future.
Źródło:
OncoReview; 2022, 12, 4; 75-82
2450-6125
Pojawia się w:
OncoReview
Dostawca treści:
Biblioteka Nauki
Artykuł
Tytuł:
A brief dive into the phenomenon of cisplatin resistance in non-small-cell lung cancer
Autorzy:
Sobczak, Maciej
Powiązania:
https://bibliotekanauki.pl/articles/1830652.pdf
Data publikacji:
2021-09-29
Wydawca:
Uniwersytet Łódzki. Wydawnictwo Uniwersytetu Łódzkiego
Tematy:
non-small-cell lung cancer
cisplatin
cisplatin resistance
Opis:
Lung cancer is one of the most lethal types of cancer due to a lack of proper treatment. The rare presence of molecular therapy targets forces the use of platinum-based drugs. Cisplatin, approved by the USA as an anticancer therapy in the 1970s, is still one of the most prominent therapies against lung cancer. Unfortunately, the biggest limitation of cisplatin-based therapy is the development of cisplatin resistance. Cancer cells overcome the vast DNA damage caused by the drug in a variety of ways such as detoxication and extracellular transport of the drug, enhanced repair mechanisms, omitting apoptosis and epigenetic alterations. Chemotherapy resistance is an issue that so far cannot be dealt with. Nevertheless, better understanding of the molecular pathways behind cisplatin resistance brings hope for better therapy outcomes in lung cancer patients.
Źródło:
Acta Universitatis Lodziensis. Folia Biologica et Oecologica; 2021, 17; 37-41
1730-2366
2083-8484
Pojawia się w:
Acta Universitatis Lodziensis. Folia Biologica et Oecologica
Dostawca treści:
Biblioteka Nauki
Artykuł
Wyświetlanie 1-15 z 16

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies